LYEL logo

Lyell Immunopharma (LYEL) Company Overview

Profile

Full Name:

Lyell Immunopharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

June 17, 2021

Indexes:

Not included

Description:

Lyell Immunopharma focuses on developing innovative cell therapies to treat cancer. The company aims to enhance the body’s immune response against tumors by using advanced technology to improve T-cell functions, offering new hope for patients with difficult-to-treat cancers.

Key Details

Price

$0.66

Annual Revenue

$130.00 K(-99.85% YoY)

Annual EPS

-$0.93(-25.68% YoY)

Annual ROE

-31.53%

Beta

1.97

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Feb 28, 2025

Recent annual earnings:

Feb 28, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 12, 24 HC Wainwright & Co.
Neutral
Oct 30, 24 B of A Securities
Underperform
Oct 28, 24 HC Wainwright & Co.
Neutral
Aug 19, 24 HC Wainwright & Co.
Neutral
Jun 27, 24 HC Wainwright & Co.
Neutral
Jun 27, 24 B of A Securities
Buy
May 7, 24 HC Wainwright & Co.
Buy
Feb 29, 24 HC Wainwright & Co.
Buy
Nov 9, 23 HC Wainwright & Co.
Buy
Aug 28, 23 JP Morgan
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Lyell Immunopharma?
  • Does Lyell Immunopharma pay dividends?
  • What sector is Lyell Immunopharma in?
  • What industry is Lyell Immunopharma in?
  • What country is Lyell Immunopharma based in?
  • When did Lyell Immunopharma go public?
  • Is Lyell Immunopharma in the S&P 500?
  • Is Lyell Immunopharma in the NASDAQ 100?
  • Is Lyell Immunopharma in the Dow Jones?
  • When was Lyell Immunopharma's last earnings report?
  • When does Lyell Immunopharma report earnings?
  • Should I buy Lyell Immunopharma stock now?

What is the ticker symbol for Lyell Immunopharma?

The ticker symbol for Lyell Immunopharma is NASDAQ:LYEL

Does Lyell Immunopharma pay dividends?

No, Lyell Immunopharma does not pay dividends

What sector is Lyell Immunopharma in?

Lyell Immunopharma is in the Healthcare sector

What industry is Lyell Immunopharma in?

Lyell Immunopharma is in the Biotechnology industry

What country is Lyell Immunopharma based in?

Lyell Immunopharma is headquartered in United States

When did Lyell Immunopharma go public?

Lyell Immunopharma's initial public offering (IPO) was on June 17, 2021

Is Lyell Immunopharma in the S&P 500?

No, Lyell Immunopharma is not included in the S&P 500 index

Is Lyell Immunopharma in the NASDAQ 100?

No, Lyell Immunopharma is not included in the NASDAQ 100 index

Is Lyell Immunopharma in the Dow Jones?

No, Lyell Immunopharma is not included in the Dow Jones index

When was Lyell Immunopharma's last earnings report?

Lyell Immunopharma's most recent earnings report was on Feb 28, 2025

When does Lyell Immunopharma report earnings?

The date for Lyell Immunopharma's next earnings report has not been announced yet

Should I buy Lyell Immunopharma stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions